Business Wire

New Xerox Team Availability App Supports Flexible Workplace Needs

25.6.2020 15:37:00 EEST | Business Wire | Press release

Share

Today, Xerox announced the launch of its Team Availability App, a quick-to-deploy, real-time solution for organizations that need to understand employee availability and location. Knowing where and whether employees are working is critical to managing flexible work environments, where the percentage of employees sharing time between home and work locations grows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005437/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Knowing where and whether employees are working is critical to managing flexible work environments, where the percentage of employees sharing time between home and work locations grows. (Photo: Business Wire)

Organizations are actively supporting and investing in technology solutions for a hybrid workforce. A recent global business survey commissioned by Xerox shows 58% of respondents plan to change their work from home policy within the next year. This new acceptance of a hybrid workforce has also revealed technology gaps, with companies increasing investment in remote technology resources (55%) or a hybrid of remote and in-office resources (40%).

"Managing a distributed workforce during a continued pandemic presents unique challenges no organization has experienced before," said Joanne Collins Smee, executive vice president and chief commercial, SMB and channels officer, Xerox. "Organizations need to know who is available and where so they can make better decisions when allocating resources and work. This tool provides real-time knowledge to managers with distributed employee populations."

Unlike other attendance management tools, which need to plug into IT infrastructure and take weeks to implement, the Team Availability App is ready in just hours. Once populated, the app provides authorized users with customizable and privacy-protected data for strategic decision making. Xerox is rolling out the app across the company to support its Path Forward plans to manage a phased approach to returning to the workplace safely. Xerox is leveraging the app with its own employee population to conduct daily health checks for exposure related to COVID-19. Tracking of this activity allows for a safe and phased return to the workplace.

The U.K.'s prestigious Imperial NHS Trust was the first organization to pilot the Xerox Team Availability App to access the status of essential workers across the Trust and its newly assigned locations at the height of the pandemic.

"It's important for a healthcare provider to know which caregivers are available when to support patients, and that's even more critical in a pandemic," said Linda Watts, joint clinical systems program manager, Imperial NHS Trust & Chelsea & Westminster NHS Foundation Trust, head of health records, Imperial College Healthcare NHS Trust. "The Xerox Team Availability App was deployed at lightning speed, and we got updates from staff on their availability in real-time. As a result, we could always make sure our patients were covered."

The Xerox Team Availability App is a GDPR-compliant SaaS offering with a subscription-based model that allows customers to sign up for as long as required. It's available now on the App Store and Google Play Store.

For more information and additional results from the Xerox Future of Work study, visit www.Xerox.com/MakeNowWork.

About Xerox

Xerox makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, the ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com.

Xerox Future of Work Survey Methodology

The survey of 600 respondents located in the U.S., Canada, UK, Germany and France was conducted by independent research firm Vanson Bourne in May 2020. Respondents included IT decision-makers (including senior C-level professionals), all from organizations with at least 500 employees across a range of sectors, including business and professional services, retail, health care, financial services, and travel and hospitality.

Note: To receive RSS news feeds, visit https://www.news.xerox.com. For open commentary, industry perspectives and views, visit http://twitter.com/xerox, http://www.facebook.com/XeroxCorp, https://www.instagram.com/xerox/, http://www.linkedin.com/company/xerox, http://www.youtube.com/XeroxCorp.

Xerox® is a trademark of Xerox Corporation in the United States and/or other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Sonia Panchal, Xerox, +44 (0)7713 191581, sonia.panchal@xerox.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye